Funding Neuro are launching an appeal to bring one of the world’s most advanced immunotherapy trials for glioblastoma to Scotland. Funding Neuro is raising the £500,000 required to complete the trial. The trial will run at Ninewells Hospital in Dundee led by Dr Kismet Hossain-Ibrahim (FRCS (SN), PhD) Consultant Neurosurgeon.
The trial will involve ten patients, who will have their own immune system used to target this deadly brain tumour.
The trial will use a new vaccine targeting Cytomegalovirus (CMV) for Glioblastoma, which has been developed in the United States. This is an exciting opportunity to help translate this discovery from the lab into an effective treatment for patients.
Help us to reach our target
To donate to the Glioblastoma Immunotherapay click the link below
What is Glioblastoma
Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive cancer that begins within the brain. Initially, signs and symptoms of glioblastoma are non-specific. They may include headaches, personality changes, nausea, and symptoms similar to those of a stroke. There is no clear way to prevent the disease.
Dr John Howard Sampson, M.D., Ph.D, M.B.A, M.H.S.c, is the chief of the department of neurosurgery at Duke University where he serves as a professor of surgery, biomedical engineering, immunology, and pathology said “There have been surprisingly promising clinical outcomes in small studies of this investigational vaccine, which certainly support these advanced trials. Immunotherapy is giving real hope to those with glioblastoma.”
For more information on glioblastoma visit – https://www.fundingneuro.com/glioblastoma/